摘要
背景:糖尿病2型(DMT2)是一种全球性的内分泌疾病,目前全球12个成年人中有1个受到影响,患病率仍在增加。世界卫生组织(世卫组织)宣布,作为一种流行病,这一世界范围内的健康问题将成为唯一具有这种分类的非传染性疾病。 DMT2患者出现各种并发症的风险增加,预期寿命缩短。目前可用于DMT2的主要口服降糖药物的化学组成,作用方式,安全性和耐受性各不相同。 方法:系统地搜索同行评审的科学文献和公共数据库。我们列入了最新的相关研究论文和数据,涉及本次审查的重点。使用标准工具评估检索到的论文的质量。 结果:该综述突出了具有共同靶点-DMT2的分子的化学结构多样性。所谓的传统抗糖尿病药以及最新和最少探索的药物包括多肽和氨基酸衍生物(胰岛素,胰高血糖素样肽1,二肽基肽酶-IV抑制剂,胰淀素),磺酰脲衍生物,苄基噻唑烷-2,4-二酮(过氧化物酶体增殖物激活受体-γ激动剂/格列酮类),缩合胍基核心(二甲双胍)和糖样分子(α-葡糖苷酶和钠/葡萄糖共转运蛋白2抑制剂)。 结论:随着糖尿病成为更常见的疾病,对新药理靶点的兴趣正在上升。
关键词: DMT2,过氧化物酶体增殖物激活受体-γ激动剂,二甲双胍,α-葡糖苷酶抑制剂,胰高血糖素样肽1类似物,二肽基肽酶-IV抑制剂,胰岛淀粉样多肽类似物,钠 - 葡萄糖协同转运蛋白2抑制剂。
Current Medicinal Chemistry
Title:Antidiabetics: Structural Diversity of Molecules with a Common Aim
Volume: 25 Issue: 18
关键词: DMT2,过氧化物酶体增殖物激活受体-γ激动剂,二甲双胍,α-葡糖苷酶抑制剂,胰高血糖素样肽1类似物,二肽基肽酶-IV抑制剂,胰岛淀粉样多肽类似物,钠 - 葡萄糖协同转运蛋白2抑制剂。
摘要: Background: Diabetes mellitus type 2 (DMT2) is an endocrine disease of global proportions which is currently affecting 1 in 12 adults in the world, with still increasing prevalence. World Health Organization (WHO) declared this worldwide health problem, as an epidemic disease, to be the only non-infectious disease with such categorization. People with DMT2 are at increased risk of various complications and have shorter life expectancy. The main classes of oral antidiabetic drugs accessible today for DMT2 vary in their chemical composition, modes of action, safety profiles and tolerability.
Methods: A systematic search of peer-reviewed scientific literature and public databases has been conducted. We included the most recent relevant research papers and data in respect to the focus of the present review. The quality of retrieved papers was assessed using standard tools.
Results: The review highlights the chemical structural diversity of the molecules that have the common target-DMT2. So-called traditional antidiabetics as well as the newest and the least explored drugs include polypeptides and amino acid derivatives (insulin, glucagon-like peptide 1, dipeptidyl peptidase-IV inhibitors, amylin), sulfonylurea derivatives, benzylthiazolidine- 2,4-diones (peroxisome proliferator activated receptor-γ agonists/glitazones), condensed guanido core (metformin) and sugar-like molecules (α-glucosidase and sodium/ glucose co-transporter 2 inhibitors).
Conclusion: As diabetes becomes a more common disease, interest in new pharmacological targets is on the rise.
Export Options
About this article
Cite this article as:
Antidiabetics: Structural Diversity of Molecules with a Common Aim, Current Medicinal Chemistry 2018; 25 (18) . https://dx.doi.org/10.2174/0929867325666171205145309
DOI https://dx.doi.org/10.2174/0929867325666171205145309 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulation of Plasma Non Enzimatic Antioxidant Capacity (NEAC) by Plant Foods: the Role of Polyphenol
Current Topics in Medicinal Chemistry Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Oxidative Modification of Lipoproteins: Mechanisms, Role in Inflammation and Potential Clinical Applications in Cardiovascular Disease
Current Pharmaceutical Design Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, Psychotic Onset
CNS & Neurological Disorders - Drug Targets Quality Evaluation of English Mobile Applications for Gestational Diabetes: App Review using Mobile Application Rating Scale (MARS)
Current Diabetes Reviews The Hot and Potential Targets of Type 2 Diabetes Mellitus Treatment in Recent Decade
Current Drug Targets Therapies Targeting Inflammation After Stent Implantation
Current Vascular Pharmacology Mast Cell Chymase and Tryptase as Targets for Cardiovascular and Metabolic Diseases
Current Pharmaceutical Design Perceived Barriers, Benefits, Facilitators, and Attitudes of Health Professionals Towards Multidisciplinary Team Care in Type 2 Diabetes Management: A Systematic Review
Current Diabetes Reviews PDX-1 and MafA as Potential Therapeutic Targets for Diabetes
Current Signal Transduction Therapy Non-Alcoholic Steatohepatitis: What Can We Learn from Animal Models?
Current Medicinal Chemistry Ecto-ADP-Ribosyltransferases (ARTs): Emerging Actors in Cell Communication and Signaling
Current Medicinal Chemistry Peptidomimetics and their Applications in Antifungal Drug Design
Anti-Infective Agents in Medicinal Chemistry Anti-islet Cell Antibodies in a Sample of Egyptian Females with Gestational Diabetes and its Relation to Development of Type 1 Diabetes Mellitus
Current Diabetes Reviews ABT-450: A Novel Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
Current Medicinal Chemistry Podocytes as a Target of Prorenin in Diabetes
Current Diabetes Reviews Benefits of Exercise Training in Secondary Prevention of Coronary and Peripheral Arterial Disease
Vascular Disease Prevention (Discontinued) Cellular FLICE-Like Inhibitory Protein (C-FLIP): A Novel Target for Cancer Therapy
Current Cancer Drug Targets Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism
Current Pharmaceutical Biotechnology Onychomycosis and its Chemotherapy
Current Medicinal Chemistry